Steven is the founder-CEO of CBT Advisors (www.cbtadvisors.com), a life sciences consulting firm in Cambridge, Massachusetts. He worked as a full-time biomedical writer at Nature and The Economist before becoming a venture capitalist with TVM Capital. There, his deals included Sirna Therapeutics, sold to Merck in 2006 for $1.1 billion, and Genetix Pharmaceuticals, later renamed bluebird bio, which IPO’d on NASDAQ in 2013 and reached a $2.8 billion valuation in 2015. In his practice, he applies sharp analytical skills and deep industry experience in crafting business deals, telling persuasive, impactful stories, understanding the VC and investing worlds and carrying out industry analysis on behalf of clients. His team works with biotechnology, diagnostics and health IT firms.
MEET STEVEN DICKMAN AT #KFG2018
Steven Dickman will be the presentor of the morning programme and the moderator of the panel discussion.